What have transgenic and knockout animals taught us about respiratory disease?

Respiratory Research

Domenico Spina¹  Yanira Riffo Vasquez¹ 

[1] The Sackler Institute of Pulmonary Pharmacology, King's College London, London, UK

关键词: murine;    inflammation;    cytokines;    chemokines;    asthma;   

Others  :  1227489
DOI  :  10.1186/rr17

 received in 2000-06-26, accepted in 2000-07-18,  发布年份 2000

【 摘 要 】

Over the past decade there has been a significant shift to the use of murine models for investigations into the molecular basis of respiratory diseases, including asthma and chronic obstructive pulmonary disease. These models offer the exciting prospect of dissecting the complex interaction between cytokines, chemokines and growth related peptides in disease pathogenesis. Furthermore, the receptors and the intracellular signalling pathways that are subsequently activated are amenable for study because of the availability of monoclonal antibodies and techniques for targeted gene disruption and gene incorporation for individual mediators, receptors and proteins. However, it is clear that extrapolation from these models to the human condition is not straightforward, as reflected by some recent clinical disappointments. This is not necessarily a problem with the use of mice itself, but results from our continued ignorance of the disease process and how to improve the modelling of complex interactions between different inflammatory mediators that underlie clinical pathology. This review highlights some of the strengths and weaknesses of murine models of respiratory disease.

【 授权许可】

   
2000 Current Science Ltd

【 参考文献 】

• [1]Gleich GJ: Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 2000, 105:651-663.
• [2]Romagnani S: The role of lymphocytes in allergic disease. J Allergy Clin Immunol 2000, 105:399-408.
• [3]Kemeny DM, Vyas B, Vukmanovi-Stejic M, Thomas MJ, Nobel A, Loh L-C, O'Connor BJ: CD8+ T cell subsets and chronic obstructive pumonary disease. Am J Respir Crit Care Med 1999, 160:S33-S37.
• [4]Saetta M: Airway inflammation in chronic obstructive pulmonary. Am J Respir Crit Care Med 1999, 160:S17-S20.
• [5]Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM: Asthma from bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000, 161:1720-1745.
• [6]Jeffery PK: Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998, 53:129-136.
• [7]Drazen JM: Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999, 340:197-206.
• [8]Torphy TJ, Page C: Phosphodiesterases: the journey toward therapeutics. Trends Pharmacol Sci 2000, 21:157-159.
• [9]Hamid QA, Minshall EM: Molecular pathology of allergic disease I: lower airway disease. J Allergy Clin Immunol 2000, 105:20-36.
• [10]Cieslewicz G, Tomkinson A, Adler A, Duez C, Schwarze J, Takeda K, Larson KA, Lee JJ, Irvin CG, Gelfand EW: The late, but not early, asthmatic response is dependent on IL-5 and correlates with eosinophilic infiltration. J Clin Invest 1999, 104:301-308.
• [11]Tournoy KG, Kips JC, Schou C, Pauwels RA: Airway eosinophilia is not a requirement for allergen-induced airway hyperresponsiveness. Clin Exp Allergy 2000, 30:79-85.
• [12]Temelkovski J, Hogan SP, Shepherd DP, Foster PS, Kumar RK: An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen. Thorax 1998, 53:849-856.
• [13]Mathur M, Herrmann K, Li X, Qin Y, Weinstock J, Elliott D, Monahan J, Padrid P: TRFK-5 reverses established airway eosinophilia but not established hyperresponsiveness in a murine model of chronic asthma. Am J Respir Crit Care Med 1999, 159:580-587.
• [14]Kung TT, Crawley Y, Luo B, Young S, Kreutner W, Chapman RW: Inhibition of pulmonary eosinophilia and airway hyper-responsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines. Br J Pharmacol 2000, 130:457-463.
• [15]Elias JA, Zhu Z, Chupp G, Homer RJ: Airway remodeling in asthma. J Clin Invest 1999, 104:1001-1006.
• [16]Holgate ST, Davies DE, Lackie PM, Wislon SJ, Puddicombe SM, Lordan JL: Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol 2000, 105:193-204.
• [17]Smith L, McFadden ER: Bronchial hyperreactivity revisited. Ann Allergy Asthma Immunol 1995, 74:454-469.
• [18]Hogan SP, Matthaei KI, Young JM, Koskinen A, Young IG, Foster PS: A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/C mice independently of IL-4 and IL-5. J Immunol 1998, 161:1501-1509.
• [19]Callard R, George AJT, Stark J: Cytokines, chaos and complexity. Immunity 1999, 11:507-513.
• [20]Hyland ME: A connectionist theory of asthma. Clin Exp Allergy 1999, 29:1467-1473.
• [21]Sont JK, Willems LNA, Bel EH, van Krieken JHJM, Vandenbroucke JP, Sterk PJ: Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. Am J Respir Crit Care Med 1999, 159:1043-1051.
• [22]Drazen JM, Finn PW, De Sanctis GT: Mouse models of airway responsiveness: Physiological basis of observed outcomes and analysis of selected examples using these outcome indicators. Annu Rev Physiol 1999, 61:593-625.
• [23]McLane MP, Haczku A, van de Rijn M, Weiss C, Ferrante V, MacDon-ald D, Renauld JC, Nicolaides NC, Holroyd KJ, Levitt RC: Interleukin-9 promotes allergen-induced eosinophilic inflammation and airway hyperresponsiveness in transgenic mice. Am J Respir Cell Mol Biol 1998, 19:713-720.
• [24]Milgrom H, Fick RB, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ: Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999, 341:1966-1973.
• [25]Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garrison L: Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999, 160:1816-1823.
• [26]Leckie MJ, ten Brinke A, Lordan J, Khan J, Diamant Z, Walls CM, Cowley H, Webber D, Hansel TT, Djukanovic R, Sterk PJ, Holgate ST, Barnes PJ: SB 240563 A humanized anti-IL-5 monoclonal antibody: initial single dose safety and activity in patients with asthma [abstract]. Am J Respir Crit Care Med 1999, 159:A642-.
• [27]O'Connor BJ, Hansel TT, Holgate ST, Barnes PJ: Effects of recombinant human interleukin-12 on allergen induced airway inflammation and the late phase response [abstract]. Am J Respir Crit Care Med 2000, 161:A592-.
• [28]Krieg AM: The role of CpG motifs in innate innate immunity. Curr Opin Immunol 2000, 12:35-43.